Germany-based medical device company specialising in innovative epidermal radioisotope therapies OncoBeta announced on Friday that it has expanded its Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy with the Bolzano Hospital being the latest to come on board.

The company claims that this marks a significant advancement in the availability of non-melanoma skin cancer (NMSC) treatment options within the country.

Presently, Rhenium-SCT is offered in Germany, Switzerland, Italy, Spain, United Kingdom, South Africa and Australia. It will be provided to patients at Bolzano Hospital by OncoBeta's distribution partner, DSD Pharma.

Shannon D. Brown III, OncoBeta CCO, said, 'While surgical intervention remains the standard-of-care for NMSC treatment, it often leads to suboptimal outcomes. Rhenium-SCT offers a non-surgical alternative with a simple application directly to the area needed to treat, and allows patients to resume their daily activities with minimal disruption.'